Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 1;6(11):1339–1349. doi: 10.1016/j.molmet.2017.08.010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Lixisenatide has no effect on heart rate or LVDP in isolated mouse hearts ex vivo. (A) Heart rate and left ventricular developed pressure (LVDP) in aerobic perfused ex vivo mouse hearts exposed to vehicle (Veh) or increasing doses of lixisenatide (Lixi). (B) Analysis of heart rate (upper panels) and LVDP (lower panels), at baseline and during reperfusion, following a 30 min period of no-flow global ischemia in ex vivo isolated mouse hearts that were exposed to vehicle (control), 0.5 nM GLP-1 7-36 (GLP-1), 5 nM lixisenatide (Lixi), or ischemia preconditioning (IPC). Heart rate recordings during the ischemic period (upper left panel) are very high due to quivering of the heart and have been omitted from the graph. The panels on the right depict AUC data for heart rate or LVDP at baseline and during the reperfusion period. In (A), isoproterenol (isoprot) was used as a positive control at the end of each perfusion. Values are mean ± SE; n = 5–11 hearts/group. ***p < 0.001 for IPC vs all other treatments (One-way ANOVA of AUC LVDP data).